Effects of Pilates Method and Aerobic Training in Hypertensive Subjects

Hypertension Clinical Trial

Official title:

Effects of Pilates Method and Aerobic Training in Hypertensive Subjects: a Randomized Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03214016
• Other study ID #: EPMAT
• Status: Completed
• Phase: N/A
• Start date: August 20, 2017
• Est. completion date: August 31, 2018

Study information

• Verified date: April 2020
• Source: Universidade Federal de Santa Maria
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the effects of Pilates method and aerobic training in hypertensive subjects. Half of participants will be trained with Pilates, while the other half will be trained with aerobic exercise during 8 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 31, 2018
• Est. primary completion date: May 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• subjects with high blood pressure controled by medication;

• sedentary.

Exclusion Criteria:

• IMC=30 kg/m²

• using beta blockers

• smokers or that interrupted the routine less than 6 months

• musculoskeletal diseases in evolution or with current symptomatic

• rheumatological diseases

• other cardiovascular disease

• renal disease due to hypertension

• endocrine, neurological, oncological, immunological, hematological and psychiatric diseases.

Related Conditions & MeSH terms

• Hypertension

Intervention

Other:
• Aerobic Exercise
1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
• Pilates
1 hour of Mat Pilates, 2 times a week, during 8 weeks.

Locations

Country	Name	City	State
Brazil	University Federal of Santa Maria	Santa Maria	RS

Sponsors (1)

Lead Sponsor	Collaborator
Universidade Federal de Santa Maria

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline casual systolic blood pressure at 8 weeks	It will be evaluated with oscillometric method of measuring blood pressure with an automated cuff.	baseline and 8 weeks
Primary	Change from baseline 24-hour systolic blood pressure at 8 weeks	It will be evaluated by 24-hour ambulatory BP monitoring (ABPM)	baseline and 8 weeks
Secondary	Casual diastolic blood pressure	It will be evaluated with oscillometric method of measuring blood pressure with an automated cuff.	baseline and 8 weeks
Secondary	Heart rate variability	It will be evaluated using a previously validated heart rate monitor Polar 810i, and the results will be analyzed in time- and frequency-domains.	baseline and 8 weeks
Secondary	Diastolic and mean blood pressure	It will be evaluated by 24-hour ambulatory BP monitoring (ABPM)	baseline and 8 weeks
Secondary	Functional capacity	Evaluate by Six-Minute Walk Test (6MWT)	baseline and 8 weeks
Secondary	Respiratory muscle strength	The maximal inspiratory and expiratory pressures will be evaluated with manovacuometer	baseline and 8 weeks
Secondary	Muscle strength	The muscles (quadriceps, gastrocnemius, abdominal and spine extensors) will be evaluated with dynamometer.	baseline and 8 weeks
Secondary	Flexibility	It will be evaluated by bank of Wells test.	baseline and 8 weeks
Secondary	Body Mass Index	It will be calculated as weight (kg) divided by height squared.	baseline and 8 weeks
Secondary	Oxidative damage	It will be evaluated by advanced oxidation protein products (AOPP)	baseline and 8 weeks
Secondary	Antioxidant capacity	It will be evaluated by total antioxidant capacity (TAC).	baseline and 8 weeks
Secondary	Lipid profile	By blood analysis (LDL, HDL, total cholesterol, glucose and triglycerides).	baseline and 8 weeks
Secondary	Endothelial function	By blood analysis (Nitrite measurement/NOx).	baseline and 8 weeks
Secondary	Inflammation	It will be evaluated by C-reactive protein in blood analysis	baseline and 8 weeks
Secondary	Creatinine	By blood analysis	baseline and 8 weeks
Secondary	Lactate	By blood analysis	baselina and 8 weeks
Secondary	Creatine kinase	By blood analysis	baseline and 8 weeks
Secondary	Questionnaire of Quality of life	It will be evaluated by Mini-questionnaire of Quality of Life in Hypertension (MINICHAL)	baseline and 8 weeks